RxDoctor Payments Data

Ernest Troisi, DPM

Podiatrist · Newark, DENPI 1386682904

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.7% of the total across 53 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Smith+Nephew at 39.1% of the total. 2025 is the largest year on record at $718, 3.3 times the $217 reported in 2019.

$2,066in general payments, 2019–2025

Across 53 payments — averaging $38.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$807
  • Stryker$550
  • Arthrex$187
  • Osteomed LLC$136
  • Cardiovascular Systems Inc.$128
  • Bioventus LLC$114
  • plus $145 from 2 others

What the payments were for

  • Food & beverage$2,01998%
  • Education$472%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,066 in reported general payments places this provider in the 60th percentile of 37 podiatrist providers in Delaware.

See all podiatrist providers in Delaware

Medicare billing

Part B allowed, 2024
$314,904
Medicare patients
567
Services billed
7,517

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gabapentin243$3,196
Ketoconazole111$2,277
Imiquimod40$1,523
Terbinafine Hcl51$875
Methylprednisolone95$684
Pregabalin22$566
Cephalexin44$244
Diclofenac Sodium15$171
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen31$164
Tramadol Hcl15$109
Acetaminophen-CodeineAcetaminophen With Codeine21$108
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim28$93
Allopurinol13$89
Naproxen16$69
Ciprofloxacin Hcl15$60

Paid to pharmacies, not to this prescriber.

Other podiatrist in Newark

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →